Self‐injectable DMTs in relapsing MS: NEDA assessment at 10 years in a real‐world cohort

Abstract

Multiple sclerosis (MS) is an immune-related chronic disease with demyelination and loss of axonal in the central nervous system and is an important cause of disability in young adults. This description has been applied to MS for many years. Disease-modifying therapies (DMTs) are used in MS to reduce the relapse rate and improve quality of life. It comprises immunomodulators and immunosuppressants. The hypothesis of treatments aimed at preventing new lesions and sequelae, and slowing the poor course of the disease remains a current one. Over time, the MS patient profile has changed, the rate of physically disabled patients has decreased, and the rate of ambulatory patients has increased. 1 The effectiveness of interferon-beta (IFN-B), the first of the self-injectable DMTs, was evaluated regarding the presence of attack in the first year, disease progression with the expanded disease status scale (EDSS), and the presence of new T2 lesions on magnetic resonance imaging (MRI) of the brain. 2 While disease activity and progression were previously evaluated using